According to a new report published by Allied Market Research, titled, “Insomnia Market,” The insomnia market size was valued at $4.3 billion in 2020, and is estimated to reach $6.3 billion by 2030, growing at a CAGR of 3.9% from 2021 to 2030. Insomnia is a sleep disorder wherein people face problem to fall asleep or remain asleep. The major causes of insomnia, include high stress levels, mental disorders, excessive consumption of caffeine and alcohol, and other medical conditions. Insomnia is categorized into three types depending on the duration of the disorder, namely, transient (few days), acute (few weeks), and chronic insomnia (few months or even years).

Download Sample Report at https://www.alliedmarketresearch.com/request-sample/2373

Key Findings of Study

  • By therapy type, the pharmacological therapy segment was the highest contributor to the market in 2020.
  • Region-wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Inhaled nitric oxide has antiviral properties and improved oxygenation. Therefore, nitric oxide is now being tested as an experimental treatment for COVID-19. It is helpful in protecting healthcare workers on the front line of the pandemic from getting sick. Further, iNO is used for the treatment of pulmonary hypertension, ARDS, and other respiratory diseases, whereas several undergoing randomized clinical trials are being conducted to investigate the role of inhaled nitric oxide in COVID-19. Moreover, key players such as Mallinckrodt have also initiated a retrospective study for the use of iNO in COVID-19 patients. Moreover, multiple ongoing clinical trials are conducted for iNO as a treatment for COVID-19 and it is being used with promising results in the patient population.

Key Market Players

  • CURRAX PHARMACEUTICALS LLC
  • EISAI, CO. LTD
  • merck kgaa, darmstadt, germany
  • MINERVA NEUROSCIENCES INC
  • Pfizer Inc.
  • Sanofi
  • Takeda Pharmaceutical Company Ltd
  • Vanda Pharmaceuticals Inc.
  • VIATRIS INC
  • zydus cadila

The global insomnia market size is driven by rise in demand for over-the-counter (OTC) sleep aids and emergence of therapeutics with fewer side effects. The rise in incidence of chronic diseases is expected to boost the market growth during the insomnia market analysis period. Drugs used for the treatment of chronic diseases casue some side effects, which also affect the patient’s quality of sleep. Furthermore, rise in stress level among youngsters also affects the quality of sleep and increase in demand for drugs propel the insomnia market growth. Moreover, rise in geriatric population, increase in healthcare expenditure, and growth in disposable income are expected to fuel the insomnia industry, and drive the growth of the market. For instance, as per the Americas Health Rankings (AHR) report, around more than 54 million adults ages 65 and older lived in the U.S. in 2020. People aged 60 and older are more susceptible to insomnia. However, side effects caused due to excessive use of sleep medication in the market are expected to hinder the market growth.

Alarming rise in prevalence insomnia, increase in demand for yoga and cognitive behavior therapy, increase in hectic work profile, and high incidence of stress in people are expected to notably contribute toward the growth of the global insomnia market during the forecast period

The insomnia market share is segmented into therapy type and region. By therapy type, the market is categorized into non-pharmacological therapy and pharmacological therapy. The pharmacological therapy segment is the highest contributor to the market growth due to increase in prevalence of insomnia. The non-pharmacological therapy segment was the major contributor in 2020, and is expected to maintain its lead during the insomnia market forecast period, owing to fewer side effects as compared to pharmacological therapy.

For Purchase Enquiry:  https://www.alliedmarketresearch.com/purchase-enquiry/2373

Other healthcare reports

Antihyperlipidemic Drugs Market

Irritable Bowel Syndrome Treatment Market

Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of “Market Research Reports” and “Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Leave a comment

Your email address will not be published. Required fields are marked *